



Press Release

MEDIAN Technologies Announces €639K Phase III Project Award

MEDIAN Technologies will provide imaging services in an oncology phase III study led by a US specialty pharmaceutical company.

SOPHIA ANTIPOLIS, France - January 29, 2014 – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has been selected to provide imaging services in a phase III clinical trial. The study is sponsored by a US-based specialty pharmaceutical company. The anticipated amount for the project is €639K (eq. \$ 870,400).

“We are proud of this new project award [] and enthusiastic about working with both our CRO strategic partner and the specialty pharmaceutical company sponsor on this phase III study”* said Fredrik Brag, Chairman and Chief Executive Officer of MEDIAN Technologies. *“This award further reinforces the value of our alliance and strengthens our commercial positioning,”* he added.

Within the framework of the study, imaging data will be acquired from approximately two dozen clinical sites, based in Europe and Asia, with anticipated total enrollment of 200 patients and a start date forecasted in Q2, 2014. MEDIAN will provide clinical site qualification and training, image data collection, quality control, centralized data storage, and Independent Central Review (ICR) services. ICR services will be performed by radiologists using MEDIAN’s Lesion Management Solutions (LMS) software. LMS is a comprehensive suite of software modules for the review of images and quantitative assessment of response to therapy in clinical trials. MEDIAN LMS provide sponsors with very accurate and reliable imaging data.

[] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.*

ALMDT
LISTED
NYSE
ALTERNEXT

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practices. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with the world’s largest CRO to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.



MEDIAN has received the label "Innovative company" by OSEO and is listed on NYSE Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).

For more information on MEDIAN, please visit: www.medianttechnologies.com

CONTACTS

MEDIAN Technologies

Fredrik Brag, CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com

Press

ALIZE RP
Caroline Carmagnol
+ 33 6 64 18 99 59
caroline@alizerp.com

Investors

ACTIFIN
Anaïs de Scitivaux
+ 33 1 56 88 11 14
adescitivaux@actifin.fr

Christian Berg
+ 33 1 70 22 53 86
christian@alizerp.com